GITNUXREPORT 2025

Clinical Trial Statistics

Over 300,000 trials annually face delays, high costs, and recruitment challenges.

Jannik Lindner

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Key Statistics

Statistic 1

The average cost to develop a new drug through clinical trials is approximately $2.6 billion

Statistic 2

About 40% of trials are funded by industry sponsors

Statistic 3

Public funding accounts for roughly 25% of clinical trial costs

Statistic 4

The remaining funding often comes from academic institutions or non-profits

Statistic 5

The median time from initial protocol development to regulatory approval is approximately 7 years

Statistic 6

Around 60% of clinical trials encounter delays related to regulatory approval processes

Statistic 7

About 50% of pharmaceutical companies plan to increase their clinical trial budgets over the next five years

Statistic 8

Nearly 90% of clinical trials are not fully compliant with all regulatory reporting requirements on time

Statistic 9

Over 300,000 clinical trials are registered globally each year

Statistic 10

Oncology trials comprise about 24% of all clinical trials

Statistic 11

The global clinical trial market size was valued at over $66 billion in 2022

Statistic 12

The FDA approved over 50 novel drugs in 2022, many of which were tested in clinical trials

Statistic 13

The top therapeutic areas by trial volume are oncology, cardiology, and infectious diseases

Statistic 14

Clinical trials focused on rare diseases account for about 7% of all trials

Statistic 15

Global clinical trial registration has increased by over 50% since 2015

Statistic 16

The global use of biomarkers in clinical trials has increased by over 40% between 2010 and 2020

Statistic 17

Around 2% of clinical trials are placebo-controlled, reflecting increasing ethical debates around placebo use

Statistic 18

The proportion of orphan drug trials has increased by over 10% annually, reflecting growing focus on rare diseases

Statistic 19

Around 80% of clinical trial participants are men, although women make up nearly half of the population

Statistic 20

The dropout rate in clinical trials is approximately 30%

Statistic 21

About 60% of clinical trials are delayed or interrupted, primarily due to recruitment challenges

Statistic 22

The average enrollment duration for a clinical trial is roughly 6 to 12 months

Statistic 23

Less than 10% of eligible patients enroll in clinical trials

Statistic 24

Patient recruitment accounts for approximately 80% of trial timelines

Statistic 25

The average age of clinical trial participants is approximately 55 years

Statistic 26

Approximately 25% of trials are conducted on pediatric populations

Statistic 27

Only about 4-6% of adult cancer patients participate in clinical trials

Statistic 28

Women are underrepresented in clinical trials for cardiovascular diseases, comprising only about 30% of participants in such studies

Statistic 29

Less than 15% of clinical trials include diverse ethnic populations, highlighting ongoing diversity challenges

Statistic 30

Patient engagement in trial design improves recruitment and retention rates by up to 20%

Statistic 31

The use of artificial intelligence in patient screening has increased trial recruitment speed by an average of 35%

Statistic 32

The percentage of global trials conducted entirely in low- and middle-income countries has risen to around 20%, increasing diversity

Statistic 33

Digital health technologies are increasingly used in trial monitoring, with about 30% adoption increase in recent years

Statistic 34

Approximately 35% of clinical trials are conducted entirely online or remotely, leveraging telemedicine technologies

Statistic 35

The use of machine learning in clinical trial design is projected to grow at a compound annual growth rate of about 25% through 2025

Statistic 36

COVID-19 pandemic accelerated remote monitoring and virtual trials, increasing virtual trial adoption by over 40%

Statistic 37

Digital endpoints are increasingly used, with over 60% of recent neurodegenerative trials incorporating digital health metrics

Statistic 38

Patient-derived xenograft models are used in about 25% of oncology trials to better understand tumor behavior

Statistic 39

The average patient monitoring in clinical trials involves over 20 different types of data collection, including lab tests, imaging, and wearable device data

Statistic 40

Approximately 86% of clinical trials are conducted in North America, Europe, and Asia

Statistic 41

The median duration of a clinical trial is about 2 years

Statistic 42

Around 70% of clinical trials fail to meet their primary endpoints

Statistic 43

The use of electronic health records has improved patient recruitment efficiency by up to 30%

Statistic 44

Around 55% of clinical trial sites are located in North America

Statistic 45

More than 60% of clinical trials are conducted in the United States

Statistic 46

Crossover trial designs are used in roughly 20% of clinical trials, especially in chronic disease studies

Statistic 47

The frequency of protocol amendments during trials ranges from 20% to 40%, often due to unforeseen data or safety issues

Statistic 48

The success rate for new drugs entering phase 3 trials is approximately 60%, the highest among sequential phases

Statistic 49

Micro-dosing studies in early phase trials involve doses less than 1/100th of pharmacologically active dose

Statistic 50

The average success rate of drugs in Phase 1 trials is approximately 60%, decreasing in later phases

Statistic 51

About 15% of clinical trials are registered on multiple platforms to increase visibility

Statistic 52

The global clinical trial workforce is estimated at over 1 million professionals worldwide, including clinical researchers, coordinators, and statisticians

Statistic 53

The average number of endpoints in a clinical trial has increased by around 15% over the last decade, complicating data analysis

Statistic 54

Over 50% of trials now incorporate some form of adaptive design to improve efficiency and success rates

Slide 1 of 54
Share:FacebookLinkedIn
Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

  • Over 300,000 clinical trials are registered globally each year
  • Approximately 86% of clinical trials are conducted in North America, Europe, and Asia
  • The median duration of a clinical trial is about 2 years
  • Around 70% of clinical trials fail to meet their primary endpoints
  • The average cost to develop a new drug through clinical trials is approximately $2.6 billion
  • Oncology trials comprise about 24% of all clinical trials
  • The global clinical trial market size was valued at over $66 billion in 2022
  • Around 80% of clinical trial participants are men, although women make up nearly half of the population
  • The dropout rate in clinical trials is approximately 30%
  • About 60% of clinical trials are delayed or interrupted, primarily due to recruitment challenges
  • The average enrollment duration for a clinical trial is roughly 6 to 12 months
  • Less than 10% of eligible patients enroll in clinical trials
  • The FDA approved over 50 novel drugs in 2022, many of which were tested in clinical trials

Did you know that over 300,000 clinical trials are registered globally each year, yet nearly 70% fail to meet their primary endpoints, highlighting both the immense challenges and groundbreaking advancements shaping the future of medical discovery?

Funding and Regulatory Aspects

  • The average cost to develop a new drug through clinical trials is approximately $2.6 billion
  • About 40% of trials are funded by industry sponsors
  • Public funding accounts for roughly 25% of clinical trial costs
  • The remaining funding often comes from academic institutions or non-profits
  • The median time from initial protocol development to regulatory approval is approximately 7 years
  • Around 60% of clinical trials encounter delays related to regulatory approval processes
  • About 50% of pharmaceutical companies plan to increase their clinical trial budgets over the next five years
  • Nearly 90% of clinical trials are not fully compliant with all regulatory reporting requirements on time

Funding and Regulatory Aspects Interpretation

With drug development costing around $2.6 billion and often stretching over seven years amid regulatory delays and funding juggling—where industry sponsors dominate but regulatory compliance lags—it's clear that turning scientific promise into approved medicine remains a high-stakes, complex, and often imperfect endeavor.

Market Trends and Therapeutic Focus

  • Over 300,000 clinical trials are registered globally each year
  • Oncology trials comprise about 24% of all clinical trials
  • The global clinical trial market size was valued at over $66 billion in 2022
  • The FDA approved over 50 novel drugs in 2022, many of which were tested in clinical trials
  • The top therapeutic areas by trial volume are oncology, cardiology, and infectious diseases
  • Clinical trials focused on rare diseases account for about 7% of all trials
  • Global clinical trial registration has increased by over 50% since 2015
  • The global use of biomarkers in clinical trials has increased by over 40% between 2010 and 2020
  • Around 2% of clinical trials are placebo-controlled, reflecting increasing ethical debates around placebo use
  • The proportion of orphan drug trials has increased by over 10% annually, reflecting growing focus on rare diseases

Market Trends and Therapeutic Focus Interpretation

With over 300,000 trials registered annually and a market surpassing $66 billion, the relentless pursuit of innovative therapies—especially in oncology and rare diseases—underscores both scientific ambition and the ethical balancing act of placebo use and trial diversity.

Participant Demographics and Enrollment

  • Around 80% of clinical trial participants are men, although women make up nearly half of the population
  • The dropout rate in clinical trials is approximately 30%
  • About 60% of clinical trials are delayed or interrupted, primarily due to recruitment challenges
  • The average enrollment duration for a clinical trial is roughly 6 to 12 months
  • Less than 10% of eligible patients enroll in clinical trials
  • Patient recruitment accounts for approximately 80% of trial timelines
  • The average age of clinical trial participants is approximately 55 years
  • Approximately 25% of trials are conducted on pediatric populations
  • Only about 4-6% of adult cancer patients participate in clinical trials
  • Women are underrepresented in clinical trials for cardiovascular diseases, comprising only about 30% of participants in such studies
  • Less than 15% of clinical trials include diverse ethnic populations, highlighting ongoing diversity challenges
  • Patient engagement in trial design improves recruitment and retention rates by up to 20%
  • The use of artificial intelligence in patient screening has increased trial recruitment speed by an average of 35%
  • The percentage of global trials conducted entirely in low- and middle-income countries has risen to around 20%, increasing diversity

Participant Demographics and Enrollment Interpretation

Despite women comprising nearly half the population, they are underrepresented in clinical trials—highlighting a persistent gap that, coupled with high dropout rates and recruitment challenges, turns the path to innovative medicine into a marathon where only a fraction of eligible patients, often aged around 55, participate, compounded further by limited diversity and the pressing need for smarter, inclusive screening methods such as AI.

Technological Innovations and Data Use

  • Digital health technologies are increasingly used in trial monitoring, with about 30% adoption increase in recent years
  • Approximately 35% of clinical trials are conducted entirely online or remotely, leveraging telemedicine technologies
  • The use of machine learning in clinical trial design is projected to grow at a compound annual growth rate of about 25% through 2025
  • COVID-19 pandemic accelerated remote monitoring and virtual trials, increasing virtual trial adoption by over 40%
  • Digital endpoints are increasingly used, with over 60% of recent neurodegenerative trials incorporating digital health metrics
  • Patient-derived xenograft models are used in about 25% of oncology trials to better understand tumor behavior
  • The average patient monitoring in clinical trials involves over 20 different types of data collection, including lab tests, imaging, and wearable device data

Technological Innovations and Data Use Interpretation

As digital health technologies infiltrate clinical trials at an accelerated pace—ranging from a 30% adoption surge in trial monitoring to over 60% of neurodegenerative studies integrating digital endpoints—it's clear that the future of medicine is being shaped not only by innovative data collection from over twenty sources per patient but also by a shift toward virtual, patient-centric, and AI-enhanced trial designs accelerated by pandemic-driven necessity.

Trial Operations and Management

  • Approximately 86% of clinical trials are conducted in North America, Europe, and Asia
  • The median duration of a clinical trial is about 2 years
  • Around 70% of clinical trials fail to meet their primary endpoints
  • The use of electronic health records has improved patient recruitment efficiency by up to 30%
  • Around 55% of clinical trial sites are located in North America
  • More than 60% of clinical trials are conducted in the United States
  • Crossover trial designs are used in roughly 20% of clinical trials, especially in chronic disease studies
  • The frequency of protocol amendments during trials ranges from 20% to 40%, often due to unforeseen data or safety issues
  • The success rate for new drugs entering phase 3 trials is approximately 60%, the highest among sequential phases
  • Micro-dosing studies in early phase trials involve doses less than 1/100th of pharmacologically active dose
  • The average success rate of drugs in Phase 1 trials is approximately 60%, decreasing in later phases
  • About 15% of clinical trials are registered on multiple platforms to increase visibility
  • The global clinical trial workforce is estimated at over 1 million professionals worldwide, including clinical researchers, coordinators, and statisticians
  • The average number of endpoints in a clinical trial has increased by around 15% over the last decade, complicating data analysis
  • Over 50% of trials now incorporate some form of adaptive design to improve efficiency and success rates

Trial Operations and Management Interpretation

Despite conducting over 86% of global trials predominantly in North America, Europe, and Asia with a median duration of two years, the clinical research enterprise faces a sobering 70% failure rate at primary endpoints—prompting increasingly adaptive designs and electronic health record integration to navigate the complex, often amended, multi-million dollar journey toward new drug approval, especially in the U.S. where more than half of the trials are based.

Sources & References